As on Wednesday, Bio-Rad Laboratories Inc (NYSE: BIO) got off with the flyer as it spiked 3.93% to $260.34, before settling in for the price of $250.50 at the close. Taking a more long-term approach, BIO posted a 52-week range of $248.22-$387.99.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that the giant of the Healthcare sector posted annual sales growth of 2.44% over the last 5 years. Nevertheless, stock’s Earnings Per Share (EPS) this year is -4.10%. This publicly-traded company’s shares outstanding now amounts to $22.94 million, simultaneously with a float of $19.18 million. The organization now has a market capitalization sitting at $7.39 billion. At the time of writing, stock’s 50-day Moving Average stood at $322.91, while the 200-day Moving Average is $320.74.
Bio-Rad Laboratories Inc (BIO) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Medical Devices industry. Bio-Rad Laboratories Inc’s current insider ownership accounts for 31.52%, in contrast to 68.05% institutional ownership.
Bio-Rad Laboratories Inc (BIO) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 2.47 per share during the current fiscal year.
Bio-Rad Laboratories Inc’s EPS decrease for this current 12-month fiscal period is -4.10% and is forecasted to reach 11.66 in the upcoming year.
Bio-Rad Laboratories Inc (NYSE: BIO) Trading Performance Indicators
Let’s observe the current performance indicators for Bio-Rad Laboratories Inc (BIO). It’s Quick Ratio in the last reported quarter now stands at 4.85. The Stock has managed to achieve an average true range (ATR) of 10.46. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 2.88. Similarly, its price to free cash flow for trailing twelve months is now 25.58.
In the same vein, BIO’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -65.04, a figure that is expected to reach 1.85 in the next quarter, and analysts are predicting that it will be 11.66 at the market close of one year from today.
Technical Analysis of Bio-Rad Laboratories Inc (BIO)
Through scrutinizing the latest numbers posted by the [Bio-Rad Laboratories Inc, BIO], it can be observed that its last 5-days Average volume of 0.34 million was better the volume of 0.24 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 12.59% While, its Average True Range was 10.20.
Raw Stochastic average of Bio-Rad Laboratories Inc (BIO) in the period of the previous 100 days is set at 8.67%, which indicates a major fall in contrast to 18.15% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 49.02% that was higher than 39.54% volatility it exhibited in the past 100-days period.
